better expect still
uncertainti horizon
net dbt
sale yoy fx vs estimate
core growth vs estimate guid gross margin
flat y/i despit posit mix shift tariff hit adj opm
estimate lower opex adj ep y/i vs
street agil rais core sale growth guid
expect rais ep guid
lsag saw flat organ sale growth y/i vs estimate biopharma rebound
environment forens grew dd chemic lag tough
comp food declin china government lab yet resum purchas management
saw sequenti improv gener drug maker china initi
round winner agil also saw broad-bas core growth dgg well ahead
est core acg ahead
encourag still bit cautiou
overal encourag biopharma improv strong demand
consum servic well steadi oper margin improv
stay cautiou near-term round expand nation link cost cut
consolid elsewher small molecul drug manufactur china food
issu linger macro uncertainti increas reiter neutral
rate increment posit exit new organ
revenu growth est vs
prior ep est increas chiefli due beat share
buyback est includ recent biotek deal po
vs prior lower multipl ebitda estimate
still in-lin peer group multipl compress recent week
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart santa clara california agil
technolog lead supplier analyt
instrument consum product
use mainli research qualiti assur
applic custom life scienc
chemic analysi industri compani
known leader life scienc
industri long histori innov
believ well posit
benefit secular posit growth trend
life scienc acquisit also
provid new opportun growth
under-penetrated market howev specif
end-market show sign volatil
see risk/reward balanc
po base ev/ebitda multipl in-lin agil life
scienc tool peer group believ justifi given agil margin expans
potenti upsid new gc product cycl macro improv solid organ
revenu growth outlook strateg option opportun capit deploy
risk po econom risk fx risk slower expect uptak new
product expans new market competit risk reduct spend
integr risk takeout specul overhang
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
